NEWS **********
biz.yahoo.com
BOSTON, Oct. 26 /PRNewswire/ -- SafeScience, Inc., (Nasdaq: SAFS - news) today announced that Brian G. R. Hughes, 44, formerly Chief Executive Officer
of the American Rocket Company (ARC), has been nominated to the Board of Directors.
''We are excited to announce the nomination of Mr. Hughes, who brings to us many years of experience building and managing innovative companies,'' said Bradley
Carver, President, SafeScience, Inc. ''His proven entrepreneurial skills in identifying business opportunities and achievements in building enormous value will be an
asset to SafeScience.''
''I believe that there is always an opportunity to apply our scientific knowledge to develop safer and better products,'' said Brian Hughes. ''SafeScience's
commitment to focusing on developing and marketing these innovative products under one world brand has enormous market potential.'''
Mr. Hughes is currently working as a consultant to several entrepreneurial businesses. As CEO of ARC, from 1989 to 1995, Mr. Hughes worked to develop and
commercialize safe, environmentally-clean, low-cost hybrid rocket propulsion. From 1984 to 1989, Mr. Hughes was the co-founder and Executive Vice President
of PTAT System, Inc., which together with C & W plc built a $500 million private, transatlantic fiber optic cable system which was sold to Sprint. Mr. Hughes
earned his Bachelor of Science from the Massachusetts Institute of Technology in 1977 and his MBA from Harvard University. Mr. Hughes is currently President
Select of the MIT Alumni Association.
SafeScience is developing and in-licensing a portfolio of efficacious agricultural, pharmaceutical, and consumer products to be marketed under the SafeScience(TM)
world brand as an alternative to conventional products employing potentially harmful chemicals. The Company's human therapeutic products include a unique
compound to treat cancer, which is in human clinical trials at the M.D. Anderson Cancer Center, as well as a promising antifungal compound, CAN-296, for the
treatment of human fungal infections. Further information is available on SafeScience's web site: safesci.com. |
